Curalc Submits Clinical Trial Application for Diabetic Nephropathy Treatment

[Asia Economy Reporter Junho Hwang] Curacle announced on the 29th that it has applied for the Phase 3 clinical trial plan (IND) for the diabetic nephropathy treatment CU01-1001 with the Ministry of Food and Drug Safety.

The company explained that this clinical trial is "a multi-center, randomized, double-blind, placebo-controlled, parallel-design Phase 3 clinical trial (Part 1) and long-term open-label extension study to evaluate the efficacy and safety of CU01-1001 administered for 24 weeks to patients with type 2 diabetic nephropathy exhibiting albuminuria."

They added, "The probability of the clinical trial drug receiving final approval as a pharmaceutical product is statistically known to be about 10%. Investors are advised to carefully consider the disclosed investment risks comprehensively through timely disclosures and business reports before investing."